Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VC-Run Dementia Discovery Fund Plays It Safe With First Investment

This article was originally published in Scrip

Executive Summary

The Dementia Discovery Fund, launched in October 2015 to much fanfare in the UK, has made its first investment in an established US biotech company – not quite the move UK scientists were hoping for. The DDF is joining a syndicate of venture capital investors in a $29.5m series D financing in Alector LLC which is using antibodies to target neurodegeneration.

You may also be interested in...



Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B

Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Topics

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel